NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totaling 893 shares, a drop of 49.8% from the September 15th total of 1,779 shares. Based on an average daily trading volume, of 2,775 shares, the short-interest ratio is presently 0.3 days.
NeuroSense Therapeutics Trading Up 30.3%
Shares of NRSNW stock traded up $0.00 during trading hours on Wednesday, hitting $0.01. 14,003 shares of the company’s stock were exchanged, compared to its average volume of 2,439. The business’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.11. NeuroSense Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.54.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The company focuses on conditions with significant unmet medical needs, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.
Its lead product candidate, PrimeC, is an investigational combination therapy designed to address multiple disease mechanisms associated with ALS. PrimeC combines ciprofloxacin and celecoxib in a proprietary formulation and has been evaluated in clinical studies involving patients with ALS.
Further Reading
- Five stocks we like better than NeuroSense Therapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
